Literature DB >> 28924736

Vasoactive Agents for Hepatorenal Syndrome: A Mixed Treatment Comparison Network Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials.

Kannan Sridharan1, Gowri Sivaramakrishnan2.   

Abstract

BACKGROUND: Hepatorenal syndrome (HRS) is a common complication among patients with cirrhosis, primarily attributable to vasodilation of renal vessels. Vasoactive agents are commonly used to treat HRS. The present network meta-analysis compares the vasoactive agents used in HRS.
METHODS: We searched electronic databases for appropriate randomized controlled clinical trials in patients with HRS, comparing active interventions with either placebo or standard of care. The primary outcome was complete HRS reversal; secondary outcomes included partial HRS reversal, mortality, adverse events, and cardiovascular adverse events. The data were pooled using a random effects model. We also carried out direct comparisons for the primary outcome with trial sequential analysis.
RESULTS: A total of 16 studies were included in the systematic review. Rates of complete HRS reversal were significantly higher with terlipressin and noradrenaline combined with albumin than with placebo (OR 6.65, 95% CI: 2.08-21.31 and 6.81, 95% CI: 1.87-24.83, respectively). No significant differences were observed in terms of mortality, partial HRS reversal, or adverse events for any of the interventions. However, cardiovascular adverse events were significantly higher with continuous-infusion terlipressin/albumin (OR 7.07, 95% CI: 1.23-40.62), bolus terlipressin/albumin (OR 7.39, 95% CI: 1.89, 28.94), octreotide/midodrine/albumin (OR 9.85, 95% CI: 1.1, 88.1), and noradrenaline/albumin (OR 15.24, 95% CI: 2.1, 112.6) than with albumin alone. Trial sequential analyses revealed adequate evidence to conclude that terlipressin combined with albumin was effective in achieving complete HRS reversal. DISCUSSION: Terlipressin combined with albumin shows strong evidence of improving short-term survival in patients with type 1 but not type 2 HRS. Through indirect comparison, noradrenaline with albumin was also associated with significant benefits in terms of HRS reversal.

Entities:  

Keywords:  cirrhosis; midodrine; noradrenaline; octreotide; terlipressin

Mesh:

Substances:

Year:  2017        PMID: 28924736      PMCID: PMC5756164          DOI: 10.1007/s11606-017-4178-8

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  32 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Hepatorenal syndrome. Definition, pathophysiology, and intervention.

Authors:  Andrew E Briglia; Frank A Anania
Journal:  Crit Care Clin       Date:  2002-04       Impact factor: 3.598

Review 3.  EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis.

Authors: 
Journal:  J Hepatol       Date:  2010-06-01       Impact factor: 25.083

Review 4.  Meta-analysis: terlipressin therapy for the hepatorenal syndrome.

Authors:  F Fabrizi; V Dixit; P Martin
Journal:  Aliment Pharmacol Ther       Date:  2006-09-15       Impact factor: 8.171

Review 5.  Hepatorenal syndrome: pathophysiology and management.

Authors:  Hani M Wadei; Martin L Mai; Nasimul Ahsan; Thomas A Gonwa
Journal:  Clin J Am Soc Nephrol       Date:  2006-07-12       Impact factor: 8.237

6.  A multiple testing procedure for clinical trials.

Authors:  P C O'Brien; T R Fleming
Journal:  Biometrics       Date:  1979-09       Impact factor: 2.571

Review 7.  Terlipressin for hepatorenal syndrome.

Authors:  Lise Lotte Gluud; Kurt Christensen; Erik Christensen; Aleksander Krag
Journal:  Cochrane Database Syst Rev       Date:  2012-09-12

8.  Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.

Authors:  Marta Cavallin; Salvatore Piano; Antonietta Romano; Silvano Fasolato; Anna Chiara Frigo; Gianpiero Benetti; Elisabetta Gola; Filippo Morando; Marialuisa Stanco; Silvia Rosi; Antonietta Sticca; Umberto Cillo; Paolo Angeli
Journal:  Hepatology       Date:  2016-02-03       Impact factor: 17.425

9.  The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.

Authors:  Brian Hutton; Georgia Salanti; Deborah M Caldwell; Anna Chaimani; Christopher H Schmid; Chris Cameron; John P A Ioannidis; Sharon Straus; Kristian Thorlund; Jeroen P Jansen; Cynthia Mulrow; Ferrán Catalá-López; Peter C Gøtzsche; Kay Dickersin; Isabelle Boutron; Douglas G Altman; David Moher
Journal:  Ann Intern Med       Date:  2015-06-02       Impact factor: 25.391

10.  Hepatorenal syndrome: outcome of response to therapy and predictors of survival.

Authors:  Jan Heidemann; Christoph Bartels; Christoph Berssenbrügge; Hartmut Schmidt; Tobias Meister
Journal:  Gastroenterol Res Pract       Date:  2015-04-23       Impact factor: 2.260

View more
  5 in total

1.  Practice guidance for the use of terlipressin for liver cirrhosis-related complications.

Authors:  Xingshun Qi; Zhaohui Bai; Qiang Zhu; Gang Cheng; Yu Chen; Xiaowei Dang; Huiguo Ding; Juqiang Han; Lei Han; Yingli He; Fanpu Ji; Hongxu Jin; Bimin Li; Hongyu Li; Yiling Li; Zhiwei Li; Bang Liu; Fuquan Liu; Lei Liu; Su Lin; Dapeng Ma; Fanping Meng; Ruizhao Qi; Tianshu Ren; Lichun Shao; Shanhong Tang; Yufu Tang; Yue Teng; Chunhui Wang; Ran Wang; Yunhai Wu; Xiangbo Xu; Ling Yang; Jinqiu Yuan; Shanshan Yuan; Yida Yang; Qingchun Zhao; Wei Zhang; Yongping Yang; Xiaozhong Guo; Weifen Xie
Journal:  Therap Adv Gastroenterol       Date:  2022-05-18       Impact factor: 4.802

2.  Fluoride varnish versus glutaraldehyde for hypersensitive teeth: a randomized controlled trial, meta-analysis and trial sequential analysis.

Authors:  Gowri Sivaramakrishnan; Kannan Sridharan
Journal:  Clin Oral Investig       Date:  2018-04-02       Impact factor: 3.573

3.  Mean arterial pressure drop is an independent risk factor of hepatorenal syndrome in patients with HBV-ACLF.

Authors:  Xingrong Zheng; Yunwen Lian; Peipei Wang; Lihua Zheng; Hewei Wu; Jiaxin Lin; Xiyao Chen; Zhiliang Gao; Liang Peng; Chan Xie
Journal:  Eur J Gastroenterol Hepatol       Date:  2022-05-01       Impact factor: 2.566

4.  High expression of type I inositol 1,4,5-trisphosphate receptor in the kidney of rats with hepatorenal syndrome.

Authors:  Jing-Bo Wang; Ye Gu; Ming-Xiang Zhang; Shun Yang; Yan Wang; Wei Wang; Xi-Ran Li; Yi-Tong Zhao; Hai-Tao Wang
Journal:  World J Gastroenterol       Date:  2018-08-07       Impact factor: 5.742

5.  Botulinum Toxin for Refractory Trigeminal Neuralgia: A Trial Sequential Analysis of Randomized Clinical Trials.

Authors:  Kannan Sridharan; Gowri Sivaramakrishnan
Journal:  J Neurosci Rural Pract       Date:  2018 Jan-Mar
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.